Access the full text.
Sign up today, get DeepDyve free for 14 days.
Anas Younes, Uma Yasothan, Peter Kirkpatrick (2022)
Brentuximab vedotinNature Reviews Drug Discovery, 11
(2015)
Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoidpapulosis
M. Duvic, M. Tetzlaff, P. Gangar, Audra Clos, D. Sui, R. Talpur (2015)
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 32
(2015)
Allogeneic stemcell transplantation inpatientswithcutaneous lymphoma: updated results from a single institution
J. Francisco, C. Cerveny, Damon Meyer, B. Mixan, D. Chace, Starr Rejniak, K. Gordon, R. DeBlanc, C. Law, S. Doronina, C. Siegall, P. Senter, A. Wahl (2017)
potent and selective antitumor activity
Youn Kim, M. Tavallaee, U. Sundram, K. Salva, G. Wood, Shufeng Li, S. Rozati, S. Nagpal, M. Krathen, S. Reddy, R. Hoppe, Annie Nguyen-Lin, W. Weng, R. Armstrong, M. Pulitzer, R. Advani, S. Horwitz (2015)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 32
W. Weng, R. Armstrong, S. Arai, C. Desmarais, R. Hoppe, Youn Kim (2013)
Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell LymphomaScience Translational Medicine, 5
S. Rozati, Youn Kim (2016)
Experimental treatment strategies in primary cutaneous T-cell lymphomasCurrent Opinion in Oncology, 28
Porcia Bradford, S. Devesa, W. Anderson, J. Toro (2009)
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases.Blood, 113 21
E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Youn Kim, R. Knobler, H. Zackheim, M. Duvic, T. Estrach, S. Lamberg, G. Wood, R. Dummer, A. Ranki, G. Burg, P. Heald, M. Pittelkow, M. Bernengo, W. Sterry, L. Laroche, F. Trautinger, S. Whittaker (2007)
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).Blood, 110 6
U Yasothan A Younes (2012)
Brentuximab vedotinNat Rev Drug Discov, 11
CG Cerveny JA Francisco (2003)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activityBlood, 102
C. Hosing, R. Bassett, B. Dabaja, R. Talpur, A. Alousi, S. Ciurea, U. Popat, M. Qazilbash, E. Shpall, Y. Oki, Y. Nieto, C. Pinnix, M. Fanale, F. Maadani, M. Donato, R. Champlin, M. Duvic (2015)
Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.Annals of oncology : official journal of the European Society for Medical Oncology, 26 12
Youn Kim, Howard Liu, S. Mraz-Gernhard, A. Varghese, R. Hoppe (2003)
Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.Archives of dermatology, 139 7
A. Cuneo, G. Castoldi (2011)
Primary cutaneous CD30+ anaplastic large cell lymphomaAtlas of genetics and cytogenetics in oncology and haematology
W. Kempf, K. Pfaltz, M. Vermeer, A. Cozzio, P. Ortiz-Romero, M. Bagot, E. Olsen, Youn Kim, R. Dummer, N. Pimpinelli, S. Whittaker, E. Hodak, L. Cerroni, E. Berti, S. Horwitz, H. Prince, J. Guitart, T. Estrach, J. Sanches, M. Duvic, A. Ranki, B. Dréno, S. Ostheeren-Michaelis, R. Knobler, G. Wood, R. Willemze (2011)
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.Blood, 118 15
Summary The patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80 years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of brentuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 1, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.